Patients' characteristics
| Characteristic . | Finding . | All patients (N = 31) . | Responders (n = 9) . | Nonresponders (n = 22) . | P* . |
|---|---|---|---|---|---|
| Gender | Females | 10 (32%) | 2 (22%) | 8 (36%) | 0.68 |
| Males | 21 (68%) | 7 (78%) | 14 (64%) | ||
| Age (y) | Median (range) | 56.7 (24.0-76.9) | 50.2 (41.4-76.0) | 57.5 (24.0-76.9) | 0.51 |
| Height (cm) | Median (range) | 172 (155-193) | 175 (160-186) | 170 (155-193) | 0.38 |
| Weight (kg) | Median (range) | 70 (46-88) | 69 (60-82) | 74 (46-88) | 0.66 |
| Body surface (m2) | Median (range) | 1.8 (1.4-2.2) | 1.8 (1.6-2.0) | 1.8 (1.4-2.2) | 0.98 |
| Cases of MEN syndrome† | MEN I | 1 (3.2%) | 0 | 1 (4.5%) | 1.0 |
| MEN IIa | 2 (6.5%) | 0 | 2 (9.1%) | 1.0 | |
| MEN IIb | 0 | 0 | 0 | 1.0 | |
| Duration of disease (y)‡ | Median (range) | 4.0 (0.1-30.8) | 1.9 (0.3-13.4) | 4.5 (0.1-30.8) | 0.51 |
| Pretreatment | Radioiodine | 3 | 2 | 1 | 0.19 |
| Radiation | 10 | 3 | 7 | 1.0 | |
| Embolization | 3 | 1 | 2 | 1.0 | |
| Chemotherapy | 8 | 2 | 6 | 1.0 | |
| Calcitonin (pg/mL) | Median (range) | 7,553 (39-61,467) | 19,700 (141-61,467) | 4,471 (39-40,000) | 0.16 |
| Creatinine (μmol/L) | Median (range) | 69 (27-115) | 73 (60-94) | 64 (27-115) | 0.19 |
| Creatinine clearance (mL/min/1.73 m2) | Median (range) | 96.3 (45.1-171.0) | 94.4 (53.9-132.7) | 99.1 (45.1-171.0) | 0.48 |
| Leukocytes (×109/L) | Median (range) | 6.8 (3.5-13.3) | 6.7 (4.5-12.8) | 6.8 (3.5-13.3) | 0.98 |
| Platelets (×109/L) | Median (range) | 274 (121-863) | 313 (223-450) | 260 (121-863) | 0.06 |
| Hemoglobin (g/dL) | Median (range) | 11.5 (6.9-17.2) | 11.5 (8.8-17.2) | 11.5 (6.9-15.2) | 0.56 |
| Scintigraphic uptake | 0 | 0 | 0 | 0 | 0.83 |
| 1 | 18 (54.8%) | 5 (55.5%) | 13 (54.5%) | ||
| 2 | 5 (16.1%) | 2 (22.2%) | 3 (13.6%) | ||
| 3 | 8 (25.8%) | 2 (22.2%) | 6 (27.3%) | ||
| Cumulative activity (GBq) | Median (range) | 12.6 (1.7-29.6) | 14.8 (3.4-15.7) | 12.2 (1.2-13.3) | 0.12 |
| Characteristic . | Finding . | All patients (N = 31) . | Responders (n = 9) . | Nonresponders (n = 22) . | P* . |
|---|---|---|---|---|---|
| Gender | Females | 10 (32%) | 2 (22%) | 8 (36%) | 0.68 |
| Males | 21 (68%) | 7 (78%) | 14 (64%) | ||
| Age (y) | Median (range) | 56.7 (24.0-76.9) | 50.2 (41.4-76.0) | 57.5 (24.0-76.9) | 0.51 |
| Height (cm) | Median (range) | 172 (155-193) | 175 (160-186) | 170 (155-193) | 0.38 |
| Weight (kg) | Median (range) | 70 (46-88) | 69 (60-82) | 74 (46-88) | 0.66 |
| Body surface (m2) | Median (range) | 1.8 (1.4-2.2) | 1.8 (1.6-2.0) | 1.8 (1.4-2.2) | 0.98 |
| Cases of MEN syndrome† | MEN I | 1 (3.2%) | 0 | 1 (4.5%) | 1.0 |
| MEN IIa | 2 (6.5%) | 0 | 2 (9.1%) | 1.0 | |
| MEN IIb | 0 | 0 | 0 | 1.0 | |
| Duration of disease (y)‡ | Median (range) | 4.0 (0.1-30.8) | 1.9 (0.3-13.4) | 4.5 (0.1-30.8) | 0.51 |
| Pretreatment | Radioiodine | 3 | 2 | 1 | 0.19 |
| Radiation | 10 | 3 | 7 | 1.0 | |
| Embolization | 3 | 1 | 2 | 1.0 | |
| Chemotherapy | 8 | 2 | 6 | 1.0 | |
| Calcitonin (pg/mL) | Median (range) | 7,553 (39-61,467) | 19,700 (141-61,467) | 4,471 (39-40,000) | 0.16 |
| Creatinine (μmol/L) | Median (range) | 69 (27-115) | 73 (60-94) | 64 (27-115) | 0.19 |
| Creatinine clearance (mL/min/1.73 m2) | Median (range) | 96.3 (45.1-171.0) | 94.4 (53.9-132.7) | 99.1 (45.1-171.0) | 0.48 |
| Leukocytes (×109/L) | Median (range) | 6.8 (3.5-13.3) | 6.7 (4.5-12.8) | 6.8 (3.5-13.3) | 0.98 |
| Platelets (×109/L) | Median (range) | 274 (121-863) | 313 (223-450) | 260 (121-863) | 0.06 |
| Hemoglobin (g/dL) | Median (range) | 11.5 (6.9-17.2) | 11.5 (8.8-17.2) | 11.5 (6.9-15.2) | 0.56 |
| Scintigraphic uptake | 0 | 0 | 0 | 0 | 0.83 |
| 1 | 18 (54.8%) | 5 (55.5%) | 13 (54.5%) | ||
| 2 | 5 (16.1%) | 2 (22.2%) | 3 (13.6%) | ||
| 3 | 8 (25.8%) | 2 (22.2%) | 6 (27.3%) | ||
| Cumulative activity (GBq) | Median (range) | 12.6 (1.7-29.6) | 14.8 (3.4-15.7) | 12.2 (1.2-13.3) | 0.12 |